 |
 |
 |
 |
|
 |
|
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| www.robbinslasersite.com |
SITE
LAST UPDATED: APRIL 15, 2003
|
Press Releases |
|
|
|
Press Release LADARVision® 4000 System Receives Space Technology Hall of Fame AwardFORT WORTH, Texas, Oct. 21 /PRNewswire-FirstCall/ -- The LADARVision(R) 4000 system, manufactured and marketed by Alcon, Inc. , has been inducted into the Space Technology Hall of Fame, a program of the Space Foundation managed in cooperation with NASA, that recognizes the innovative application of space technologies in the development of commercial products. The LADARVision(R) 4000 system, used by eye surgeons worldwide to perform LASIK or laser vision correction, employs a tracking device which uses the same laser radar technology originally developed to help NASA spacecraft rendezvous and dock with satellites during service calls. During LASIK surgery, the LADARVision(R) system's tracking device allows eye surgeons to track involuntary eye movements at a rate of 4,000 times per second, 15 times faster than any other LASIK system used today. "Accurate tracking of eye movements during laser eye surgery is a critical aspect of this delicate procedure," explains Stephen Brint, MD, one of the first surgeons in the U.S. to perform LASIK, and the lead investigator of clinical trials involving LADARVision(R). "The human eye moves 100 times per second, and, without a sophisticated tracking system to lock onto the eye and remain fixed on its movements, the laser used to reshape the cornea during LASIK could become misaligned and deliver a very poor outcome." LADARVision(R), approved by the FDA in 1998, is the only laser eye surgery system that uses this innovative laser radar tracking technology. All other LASIK systems use slower, video-based tracking systems, which require surgeons to frequently and abruptly stop the LASIK procedure when the video-based system is unable to keep pace with the eye's movements. "The advent of laser eye surgery revolutionized the field of ophthalmology, and the LADARVision(R) 4000 system, with its unique tracking technology, represents an unsurpassed technological contribution in this field," Dr. Brint says. The LADARVision(R) system was developed to work seamlessly with other anticipated advances in laser eye surgery, such as new wavefront technology recently approved by the FDA. During a wavefront-guided LASIK procedure, proper alignment of the laser beam is again crucial, as it can help to reduce visual irregularities, such as glare, halos and night vision problems. "It is a great honor for an Alcon product to be inducted into the Space Technology Hall of Fame," said Bill Barton, Vice President and General Manager, Alcon Surgical Division. "This award validates the technological achievements embodied by the LADARVision(R) system, and is an example of the creativity of our scientists in R&D, who were able to convert a seemingly unrelated technology into an important tool for ophthalmology." Alcon, Inc. is the world's leading eye care company. Alcon, which has been dedicated to the ophthalmic industry for more than 50 years, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye. About Alcon Alcon, Inc. is the world's leading eye care company. Alcon, which has been dedicated to the ophthalmic industry for over 50 years, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye. Alcon has been conducting retinal research for more than 15 years and is the world's leading provider of surgical equipment used by vitreoretinal specialists who treat patients with AMD and other retinal diseases. About the Space Foundation The Colorado Springs, Colorado-based Space Foundation is a national non- profit organization, which vigorously advances civil, commercial and national- security space endeavors and educational excellence. For more information, visit http://www.spacefoundation.org or http://www.spacetechhalloffame.org. Caution Concerning Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, relating principally to our ability to successfully market and sell the system for wavefront-guided laser eye surgery. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward- looking statements. These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Factors that might cause future results to differ include, but are not limited to, the following: general economic conditions in the United States and internationally; technological advances attained by our competitors; challenges inherent in new product marketing; and government regulation and legislation. You should read this press release with the understanding that our actual future results may be materially different from what we expect. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise. For information about Alcon, contact: Doug MacHatton (Investor Relations) 800-400-8599 News Media and other inquiries: Mary Dulle (Public Relations) 817-551-8058 or pager 817-418-8990 mary.dulle@alconlabs.com http://www.alconinc.com CONTACT: investor relations, Doug MacHatton, +1-800-400-8599, or publicrelations, Mary Dulle, +1-817-551-8058, or pager, +1-817-418-8990, ormary.dulle@alconlabs.com , both of Alcon, Inc. Website: http://www.alconinc.comWebsite: http://www.spacefoundation.org Website: http://www.spacetechhalloffame.org |
|
|
|
Press Release SPRING
AND SUMMER EYEWEAR TRENDS
|
|
|
|
Press Release ROBBINS
LASER SITE NOW USING FIRST-OF-ITS-KIND LASER EYE SURGERY SYSTEM
ROCHESTER, N.Y. - -Upstate New York residents who may be candidates for laser eye surgery now have access to the latest development in LASIK technology. Dr. Allan Robbins - founder of Robbins Laser Site and Robbins Eye Associates - is now using the first-of-its-kind, wavefront-assisted LADARVision® excimer laser system. The U.S. Food & Drug Administration recently approved this new system for wavefront-guided laser eye surgery in the treatment of nearsightedness. With this new system, made up of the LADARVision 4000® excimer laser system and the new LADARWaveT diagnostic device, surgeons can, for the first time, measure and treat visual disorders that previously could not even be detected. Robbins Laser Site is currently the only practice in upstate New York to offer the LADARVision 4000® excimer laser system and the new LADARWaveT diagnostic device. Several types of imperfections, referred to as lower- and higher-order aberrations, exist within the eye and can affect both a person's visual acuity and the quality of vision. To date, only lower-order aberrations, which include nearsightedness, farsightedness and astigmatism, could be measured and treated. However, lower-order aberrations do not account for all potential vision disorders. Higher-order aberrations can also have a significant impact on a person's quality of vision, and cannot be corrected with glasses, contacts or conventional LASIK. According to experts in the field of ophthalmology, higher-order aberrations are linked to visual disturbances such as glare and halos that may cause night vision problems and are sometimes associated with conventional LASIK surgery. The LADARVision system is the first-and-only FDA approved eye surgery system that can measure both lower- and higher-order aberrations, and can actually be used to treat each patient's unique pattern of lower- and higher-order visual errors. This highly customized approach creates a new laser eye surgery procedure, called CustomCornea®, that improves both visual acuity, which is measured against standard numerical outcomes such as 20/20, and the overall quality of vision, such as increased visual crispness and clarity. Visual acuity of 20/20, considered by most as the standard for vision, has been traditionally measured by a letter chart, which does not provide for detection of many of the disorders that may affect vision. "CustomCornea® is a tremendous breakthrough in laser eye surgery that raises the bar in this field," says Dr. Robbins. "We're excited to be the first practice in upstate New York to offer this advanced LASIK technology to area residents." In CustomCornea® clinical trials, nearly 80 percent of patients who underwent the new laser eye surgery procedure achieved 20/20 vision, but even more importantly, they reported a quality of vision superior to that achieved with conventional LASIK. "Sometimes patients complain about vision quality problems, such as not being able to see in dim or low light. This is referred to as poor contrast sensitivity," explains Robbins. "Prior to the advent of wavefront measurements, there wasn't anything we could do to measure or treat higher-order aberrations. With this technology breakthrough, we can now measure these disorders, show the patient what's going on in their eye, link that information to the laser, and actually correct higher-order aberrations that diminish contrast sensitivity. Wavefront technology enables the surgeon to improve overall vision quality better than in the past." How
It Works Dr. Allan Robbins is has been in private practice for 25 years. He is the founder of both Robbins Eye Associates and Robbins Laser Site. Robbins Laser Site, located in Webster, is the first center in the Rochester area dedicated exclusively to laser vision correction. The practice also has general ophthalmology offices in Brighton and Hornell, N.Y for the treatment of such conditions as glaucoma and cataracts. Return to the News Page |
|
|
|
Press Release NEW SIGHT SAVING TECHNOLOGY NOW AVAILABLE IN ROCHESTER - Dr. Allan Robbins Brings Advanced Glaucoma Detection and Monitoring to Robbins Laser Site ROCHESTER, N.Y. - - New sight-saving technology is now available to people in Rochester and it could help detect Glaucoma earlier. Glaucoma is the leading cause of irreversible vision loss in the United States - affecting approximately three million Americans. Unfortunately, up to half of those afflicted with glaucoma are unaware that they have the disease because Glaucoma develops without warning. Too often, treatment isn't sought until a degree of vision has deteriorated. At that point, steps may be taken to control the progression of the disease however, the vision that is noticeably impaired is lost forever. Dr. Allan Robbins is making a difference within the Rochester community in the fight against glaucoma. It is well known that the key to preventing vision loss is early glaucoma detection. And, with the purchase of the Heidelberg Retina Tomograph II (HRT II), Dr. Robbins is now able to diagnose the blinding disease at its earliest stage -often before any vision is lost. Robbins Laser Site is the only practice in Rochester to offer the comprehensive, non-invasive HRT II exam for early diagnostic and monitoring of glaucoma. The HRT II is a confocal scanning laser ophthalmoscope. It not only detects the very early stages of glaucoma, it also provides eye doctors with essential information for monitoring the disease in follow-up exams. By scanning the optic nerve and adjacent nerve fiber layer, the HRT II produces a three dimensional topographic map. It generates extremely accurate, detailed data and comprehensive analysis that simply is not possible to obtain with traditional examinations. The HRT II exam is fast, safe, and usually does not require dilating the eye. While a patient sits comfortably in a stationary position, a laser scans the eye for just a few seconds (at a lower energy level than that produced from a television remote control). Although Glaucoma can develop in anyone, there are some people considered to be at higher risk than others. Those include individuals over age 60, African-Americans over age 40, and people with high blood pressure, diabetes, or a family history of glaucoma. Dr. Allan Robbins has been in private practice for 25 years. He is the founder of both Robbins Eye Associates and Robbins Laser Site. Robbins Laser Site, founded in 2000, is the first center in the Rochester area dedicated exclusively to laser vision correction. The practice is located in Webster, N.Y. Robbins Eye Associates, established 1997, is dedicated to the practice of ophthalmology and general eye care services. The practice has offices in Brighton, N.Y. and Hornell, N.Y. Return to the News Page |
|
|
|
Press Release PROTECTING THE GIFT OF SIGHT - Local Ophthalmologist to Provide Free Glaucoma Testing for Wilson Commencement Park Residents ROCHESTER, N.Y. - As the American Academy of Ophthalmology marks Glaucoma Awareness Month, one local Ophthalmologist is lending his expertise to help members of the Rochester community in fight against this disease. Glaucoma is the leading cause of irreversible vision loss in the United States - affecting approximately three million Americans. Unfortunately, up to half of those afflicted with glaucoma are unaware that they have the disease because it develops without warning. In an effort to raise awareness - and prevent vision loss - Dr. Allan Robbins and the Robbins Eye Associate technicians will provide free glaucoma testing for the residents and staff at Wilson Commencement Park. Wilson Commencement Park (WCP) is a supported housing program with the mission of offering support for low-income, single-parent families to become and remain economically and socially self-sufficient. "There are far too many Americans at risk for losing their vision to glaucoma simply because they don't know they have the disease," says Dr. Allan Robbins. "The earlier glaucoma is diagnosed, the easier it is to treat, and the more likely you are to retain your vision." Although Glaucoma can develop in anyone, there are some people considered to be at higher risk than others. Those include African-Americans over age 40, individuals over age 60, and people with high blood pressure, diabetes, or a family history of glaucoma. The federal government recently acknowledged the key role early detection plays in the successful treatment of glaucoma when it approved new Medicare legislation calling for coverage of eye exams for those at a higher risk of developing glaucoma. The American Academy of Ophthalmology worked for three years to get this benefit approved, and it is expected to help save the sight of thousands of citizens. Dr. Allan Robbins has been in private practice for 25 years. He is the founder of both Robbins Eye Associates and Robbins Laser Site. Robbins Laser Site, founded in 2000, is the first center in the Rochester area dedicated exclusively to laser vision correction. The practice is located in Webster, N.Y. Robbins Eye Associates, established 1997, is dedicated to the practice of ophthalmology and general eye care services. The practice has offices in Brighton, N.Y. and Hornell, N.Y. Return to the News Page |
|
|
|
Press Release MORE THAN ONE MILLION AMERICANS AT RISK FOR LOSING THEIR VISION TO GLAUCOMA - January Marks Glaucoma Awareness Month ROCHESTER, N.Y. - As we mark this year's observance of Glaucoma Awareness Month, there are still far too many Americans at risk for losing their vision to glaucoma simply because they don't know they have the disease. Glaucoma is the leading cause of irreversible vision loss in the United States - affecting approximately three million Americans. Unfortunately, up to half of those afflicted with glaucoma are unaware that they have the disease because it develops without warning. Too often, treatment isn't sought until a degree of vision has deteriorated. At that point, steps may be taken to control the progression of the disease however, the vision that is noticeably impaired is lost forever. That's why the American Academy of Ophthalmology is urging Americans to get an eye exam, especially if you are at risk for developing glaucoma. The good news is that there is no better time to be treated for this disease. New advances in medical research are helping Eye M.D.s (ophthalmologists) treat glaucoma more effectively and with fewer side effects. The key to treatment is early diagnosis. The earlier glaucoma is diagnosed, the easier it is to treat, and the more likely you are to retain your vision. The federal government recently acknowledged the key role early detection plays in the successful treatment of glaucoma when it approved new Medicare legislation calling for coverage of eye exams for those at a higher risk of developing glaucoma. The Academy worked for three years to get this benefit approved, and it is expected to help save the sight of thousands of senior citizens. In addition, The Foundation of the American Academy of Ophthalmology will later this month launch The Glaucoma Project through its national public service program, EyeCare AmericaTM, to provide glaucoma information and referral for qualified people at increased risk for developing glaucoma. Individuals who call the toll-free helpline at 800/391-EYES (3937) are screened for glaucoma risk factors. Eligible callers at increased risk are matched with a nearby volunteer Ophthalmologist who will provide a glaucoma eye examination and initiate necessary treatment. To be eligible, callers must be U.S. citizens/legal residents; not have had an eye exam in the past 12 months; and not belong to a doctor-restricted HMO plan or receive VA eye care benefits. The helpline is accessible 24 hours a day, seven days a week. African-Americans are at a higher risk of developing glaucoma than other racial groups. Also, anyone with a close relative who has it -- a father, mother or sibling -- is at risk. Older people, those with diabetes and people who have been taking steroid medication for a long time are also at risk. If you fall into any of these categories, talk to your Ophthalmologist about how often you should have your eyes examined. Glaucoma is a group of diseases typically associated with elevated pressure inside the eye, which can damage the optic nerve and cause vision loss. While there are usually no warning signs, some symptoms may occur in the later stages of the disease, such as loss of peripheral vision, difficulty focusing on close work, seeing halos around lights and frequent changes of prescription glasses. However, by the time you realize you're losing your vision, the vision you lost is gone forever. Glaucoma has blinded 80,000 Americans. Don't become a statistic. Know your risk and have your eyes examined regularly. A pressure check alone is insufficient to detect glaucoma. It's important you receive an appropriate evaluation from an Ophthalmologist if you are at a higher risk of developing glaucoma. Dr. Allan Robbins received his MD degree from the Albert Einstein College of Medicine and completed his Ophthalmology residency at New York Medical College. He later completed a fellowship in Cornea and External Disease at the University of Rochester, where he is currently an Assistant Clinical Professor. Dr. Robbins is a board-certified LASIK surgeon and Fellow of the American College of Surgeons. He has over 15 years of experience performing all types of refractive surgery. Dr. Allan Robbins is the founder of Robbins Laser Site, founded in 2000. His practice is the first center in the Rochester area dedicated exclusively to laser vision correction. The practice has offices in Webster, Brighton and Hornell, N.Y. Return to the News Page |
|
|
|
Press Release RING IN THE NEW YEAR SAFELY ROCHESTER, N.Y. - This New Year's Eve, as you ring in the promise and hope of the New Year, make sure you do it safely. Every year, people suffer serious, blinding eye injuries from champagne corks and fireworks. That's why the American Academy of Ophthalmology, is urging Americans to learn the proper way to open a bottle of champagne, and to attend only professional fireworks displays. Warm bottles of champagne, coupled with bad technique, can cause serious eye injuries, such as ruptured globes, detached retinas and painful bruising. Here's a safe way to open a bottle of bubbly:
If you're interested in celebrating with fireworks, please attend only professional fireworks displays. Here are a few facts about fireworks to keep in mind:
Dr. Allan Robbins received his MD degree from the Albert Einstein College of Medicine and completed his Ophthalmology residency at New York Medical College. He later completed a fellowship in Cornea and External Disease at the University of Rochester, where he is currently an Assistant Clinical Professor. Dr. Robbins is a board-certified LASIK surgeon and Fellow of the American College of Surgeons. He has over 15 years of experience performing all types of refractive surgery. Dr. Allan Robbins is the founder of Robbins Laser Site, founded in 2000. His practice is the first center in the Rochester area dedicated exclusively to laser vision correction. The practice has offices in Webster, Brighton and Hornell, N.Y. Return to the News Page |
|
|
|
Press Release YEARLY EXAMS TO HELP CURB DIABETIC EYE DISEASE - November is Diabetic Eye Disease Awareness Month ROCHESTER, N.Y. - Diabetes is a growing epidemic in America. About 16 million in the United States have the disease, and half of them are at risk of losing their vision because they don't know they have diabetes. What's more, those numbers are growing, thanks to the expanding older population in America, increasing rates of obesity and a longer life span. Diabetic retinopathy, an eye problem associated with diabetes, is the leading cause of new cases of blindness among adults in the United States each year, accounting for 8,000 cases annually. The good news is that vision loss from diabetic retinopathy can be prevented if it's caught and treated in time. To mark November's designation as Diabetic Eye Disease Awareness Month, the American Academy of Ophthalmology - the Eye M.D. association - reminds Americans with diabetes to have a dilated eye exam every year, and to keep blood sugar levels under control through diet and exercise. It is important to dilate the pupils when examining eyes of people with diabetes to get an adequate view of the retina, the nerve layer that lines the inside of the eye. Without dilating the eye, it's like looking inside a room through a keyhole instead of an open door. Unfortunately, a recent study found that more than one-third of those diagnosed with the disease don't get yearly-dilated eye exams, as recommended by the American Diabetes Association and the American Academy of Ophthalmology. Treatment is most effective in saving vision if diabetic eye disease is diagnosed in the early stages. Previous studies have shown that effective treatments for diabetic retinopathy can reduce severe vision loss by up to 94 percent. The longer a person has diabetes, the greater his or her risk for developing diabetic retinopathy. However, diabetic retinopathy not only affects people who have had diabetes for many years, it can also appear within the first year or two after the onset of the disease. For some people, diabetic retinopathy -a degenerative disease of the retina - is one of the first signs that they have diabetes. Other ways to reduce the risk of eye disease:
The first step in preventing complications is knowing you have the disease. Since some 8 million Americans have diabetes, but do not know it, it's important for all healthy adults over the age of 45 to have a blood sugar test once every three years to be screened for diabetes. If you're diagnosed with diabetes, schedule eye exams once a year or as often as your Ophthalmologist suggests and monitor your blood sugar and keep it under control through diet and exercise. Dr. Allan Robbins received his MD degree from the Albert Einstein College of Medicine and completed his Ophthalmology residency at New York Medical College. He later completed a fellowship in Cornea and External Disease at the University of Rochester, where he is currently an Assistant Clinical Professor. Dr. Robbins is a board-certified LASIK surgeon and Fellow of the American College of Surgeons. He has over 15 years of experience performing all types of refractive surgery. Dr. Allan Robbins is the founder of Robbins Laser Site, founded in 2000. His practice is the first center in the Rochester area dedicated exclusively to laser vision correction. The practice has offices in Webster, Brighton and Hornell, N.Y. Return to the News Page |
|
|
|
Press Release PROTECT THE GIFT OF SIGHT - October is Family Eye Care Month ROCHESTER, N.Y. - Eye conditions and diseases that can rob your family of their vision can strike at any time in life, from newborn to old age. In honor of Family Eye Care Month, celebrated throughout the month of October, Eye M.D.s across the country are urging Americans to take care of their eyes, as well as the eyes of their family. Pay attention to warning signs and visit an Eye M.D. regularly. Many people associate eye problems with getting older. While it's true that seniors are at higher risk for a lot of eye problems, some of those problems actually start earlier and vision loss could have been prevented if the problem was caught sooner. Preschoolers, senior citizens and people with diabetes and other with high risk factors for certain eye problems all need regular eye care. Too often they don't get it, and the sad result is vision loss. Toddlers should be screened for common childhood eye problems, like strabismus (crossed eyes) and amblyopia (lazy eye), as well as refractive errors such as nearsightedness and farsightedness before the age of 5. Some warning signs that your child may have vision problems include wandering or crossed eyes, a family history of childhood vision problems, a disinterest in reading or viewing distant objects and squinting or turning the head in an unusual manner while watching TV. Most young people have healthy eyes, but they still need to take care of their vision. In young adulthood, the major danger to the eyes is accidental injury. Sports, household accidents and even jump-starting a car can cause devastating eye injuries leading to vision loss. Remember to wear protective eyewear for all activities that present a risk of eye injury. Check with your Eye M.D. for a recommendation on protective eyewear appropriate for your activities. Even the young adult and middle age groups can be affected by eye problems. Those at risk for disease include African-Americans over age 40 (glaucoma), people with diabetes (diabetic retinopathy) and those with a family history of eye problems. If you fall into one of these groups, check with your Eye M.D. to find out how often you need to have a complete eye exam. Seniors over age 65 should be examined at least every one to two years for cataracts, glaucoma, macular degeneration and other eye conditions. Those with diabetes should be examined every year. Protecting your eyes from accidents, and early detection and treatment of eye problems are the best ways for you and your family to take care of your vision throughout life. So if you or your family are at risk for eye disease or experience any eye problems, visit your Eye M.D. Dr. Allan Robbins received his MD degree from the Albert Einstein College of Medicine and completed his Ophthalmology residency at New York Medical College. He later completed a fellowship in Cornea and External Disease at the University of Rochester, where he is currently an Assistant Clinical Professor. Dr. Robbins is a board-certified LASIK surgeon and Fellow of the American College of Surgeons. He has over 15 years of experience performing all types of refractive surgery. Dr. Allan Robbins is the founder of Robbins Laser Site, founded in 2000. His practice is the first center in the Rochester area dedicated exclusively to laser vision correction. The practice has offices in Webster, Brighton and Hornell, N.Y. Return to the News Page |
|
|
|
Press Release ROBBINS LASER SITE NOW USING NEW LADARVISION LASER EYE SURGERY SYSTEM LADARVision is the Most Advanced Excimer Laser System Available to Eye Surgeons Rochester, NY (8/8/01) - Rochester-area residents contemplating LASIK surgery but waiting for newer technology now have access to the most advanced excimer laser. Dr. Allan Robbins recently purchased and installed the LADARVision 4000 excimer laser system, which provides unparalleled surgical precision to eye surgeons and their patients. This is the first LADARVision installation in the Upstate region. "With our new LADARVision system, we are now able to offer our laser vision patients treatments with the most advanced excimer laser system available today. LADARVision has the broadest range of FDA approvals with the only eye tracker proven in clinical trials to improve outcomes" states Dr. Robbins. Unlike all other excimer laser systems, the LADARVision system uses a sophisticated laser radar system to track eye movements. LADARVision measures the position of the eye 4000 times per second and aligns the laser beam with the eye via technology developed by NASA. The LADARVision 4000 acquires a "lock" on the eye much like a missile homing in on a target and does not allow the laser to fire unless the eye position is precisely computed for each and every laser pulse. For comparison, " If the earlier broad beam lasers are like a 747, and the more recent flying spot lasers are a Concord, then the LADARVision system is the Space Shuttle," says Dr. Robbins. "All patients who undergo laser eye surgery will experience eye movement during the procedure," explains Dr. Robbins. "During surgery, these movements can materially affect the placement of the laser beam and result in decreased visual acuity or difficulty with night vision. With this system, every patient we treat is able to relax during the procedure and know that they will get the best possible results from the surgery." Guided by the system's active eye tracker, the LADARTracker, this new excimer laser system has a cool, small spot laser beam (less than 1 millimeter wide), which reshapes the cornea, removing less corneal tissue than the width of a single human hair. This offers a level of precision previously unavailable to patients who undergo laser vision correction. LADARVision also reduces the likelihood of nighttime glare and halos often experienced following treatment with other laser systems. In addition to providing superior clinical results, LADARVision is approved to treat more visual acuity problems than any other excimer laser. LADARVision is approved by the Food & Drug Administration (FDA) for the treatment of myopia (nearsightedness) with or without astigmatism and hyperopia (farsightedness) with or without astigmatism - and it is the only laser with an FDA approval for mixed astigmatism. "Given its broad treatment range, the new LADARVision system increases our ability to provide a customized treatment plan for a wide range of visual acuity problems," says Dr. Robbins. "Patients formerly outside the range of other lasers are easily corrected with the LADARVision 4000." LADARVision, manufactured and marketed by Alcon Summit Autonomous, is an important new advance in laser eye surgery. Alcon is the global leader in eye care products and just recently began marketing the new system to eye surgeons nationwide. Allan M. Robbins, MD is a board-certified LASIK surgeon and former investigator for VISX during the initial FDA clinical trials. He has also served as a scientific consultant for Phoenix Laser and LaserSight Technologies, Inc. In June of 2000, he was the first surgeon in the area to perform LASIK with a flying spot laser. Robbins Laser Site is located on Empire Boulevard, Webster. The next free informational seminar will be help on August 13th at 6:00 PM. Return to the News Page |
|
|
|
Press Release SOURCE: LaserSight, Inc. US Patent and Trademark Office Confirms LaserSight's Broad Exclusive Patent Rights to Scanning Laser Technology for Corneal Ablation WINTER PARK, Fla., March 2 /PRNewswire/ -- LaserSight® Incorporated (Nasdaq: LASE - news) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance, thereby completing its examination of LaserSight's reissue application for the Company's U.S. Patent No. 5,520,679, known as the '679 patent. After a more than 2 1/2 year review of the reissue application, including detailed analysis of a number of public protests filed by a third party, the Patent and Trademark Office has confirmed the Company's broad patent rights to precision beam microspot scanning laser refractive surgery and issued LaserSight 68 additional patent claims. Prior to the reissue, the original '679 patent included one independent claim and 23 total claims, whereas the reissue application adds nine new independent claims, and a total of 68 additional claims to better encompass the breadth of technology to which LaserSight is entitled. The 23 original claims remain essentially unchanged. Michael R. Farris, president and chief executive officer of LaserSight Incorporated, commented, ``This reissue will allow LaserSight to protect the uniqueness of its LaserScan LSX's precision beam microspot scanning technology. The value of LaserSight's intellectual property portfolio has been enhanced by this Notice of Allowance. During prosecution our additional claims were thoroughly reviewed by the Patent and Trademark Office and we successfully overcame a third party's spirited challenge to our reissue.'' The Patent and Trademark Office allows reissue applications to be filed subsequent to a patent being issued to allow a patent owner to broaden claims that may have been constructed too narrowly in the original patent. The Notice of Allowance of LaserSight's reissue application confirms that the original '679 claims were, indeed, narrower than necessary, and the claims added during the reissue have strengthened and expanded the scope of the patent's coverage. The fundamental teachings of the original '679 patent encompass a refractive laser system utilizing an excimer laser with a low fluence and high repetition rate that ablates corneal tissue using small pulses delivered to the corneal surface in an overlapping pattern. Through the reissue process, LaserSight was able to broaden several elements of the '679 Patent's original claims by removing certain restrictive elements. As an example, LaserSight now owns exclusive rights to methods for ablating tissue which comprise the provision of a basic laser having a pulsed output laser beam of a fundamental ultraviolet wavelength of 193 nm exiting from an output window of the basic laser, and a repetition rate of 1 Hz to 1000 Hz; the focusing of the pulsed output laser beam onto the tissue to a predetermined generally fixed spot size; and the scanning of the pulsed output laser beam, through known positions of an optical device moved by galvanometric forces, into a substantially overlapping pattern of beam pulses on the tissue such that adjacent ablation spots on a single ablation layer of the tissue significantly overlap one another and remove from 0.05 to 0.5 microns of tissue per pulse. LaserSight will be notifying the other laser manufacturers as to the broad claims added to the '679 Patent as a result of the reissue. The Company's LSX excimer laser system offers refractive surgeons a unique combination of patented features not available with any other refractive laser currently available in the U.S. market. These features include the lowest laser fluence (90 millijoules per square centimeter) delivered in a true gaussean 0.8 mm precision scanned microspot beam, the highest laser pulse repetition rate (200 Hz) approved by the FDA and proprietary patented beam scanning patterns that optimize refractive outcomes and smoothness of the corneal surface. Mr. Farris continued, ``The smoothness and precision available with the microspot scanning technology incorporated into our LaserScan LSX has become an important factor when surgeons are considering a laser purchase. It is recognized that a smooth and uniform ablation must be achieved to deliver the high quality custom ablation procedures the market is seeking. The increasing recognition and acceptance of scanning laser technology is apparent from the number of our competitors who have introduced some form of a scanning laser system into the U.S. market.'' Mr. Farris concluded, ``The allowance of this patent marks the beginning of a new era of next generation technologies and patents for laser refractive surgery as refractive surgeons move away from the prior generation of broad beam lasers and their related patents.'' LaserSight is a leading supplier of quality technology solutions for laser vision correction. Its products include the LaserScan LSX precision beam scanning spot system, its international research and development activities related to the Astra family of products used to perform custom ablation procedures know as CustomEyes(TM) and its MicroShape(TM) family of keratome products. In the United States, the Company's LaserScan LSX excimer laser system operating at 200 Hz is approved for the treatment of low to moderate myopia by photorefractive keratectomy. The Astra family of products includes the AstraMax(TM) diagnostic work station designed to provide precise diagnostic measurements of the eye and the AstraPro(TM) software, a surgical planning tool that utilizes advanced levels of diagnostic measurements for the planning of custom ablation treatments. The Company has received notification from the FDA that it may begin commercial distribution of its AstraMax(TM) diagnostic workstation, and has begun international clinical testing of its AstraPro planning software. The MicroShape family of keratome products includes the UltraShaper(TM) durable keratome, the UniShaper® single-use keratome and UltraEdge® keratome blades. This press release contains forward-looking statements regarding future events and future performance of the Company, including statements with respect to the '679 Patent, the reissue proceeding related to the '679 Patent, other intellectual property matters, regulatory approvals and commercialization of products, which involve risks and uncertainties that could materially affect actual results. Such statements are based on Management's current expectations and actual results could differ materially. A factor that could affect the results is any delay in reissuance of the patent on the part of the U.S. Patent and Trademark Office. Investors should refer to documents that the Company files from time-to-time with the Securities and Exchange Commission for a description of certain factors that could cause the actual results to vary from current expectations and the forward looking statements contained in this press release. Such filings include, without limitation, the Company's Form 10-K, Form 10-Q and Form 8-K reports. SOURCE: LaserSight, Inc. Return to the News Page |
|
|
|
Eastern Time Company Press Release SOURCE: LaserSight Incorporated LaserSight Receives FDA Clearance For Distribution Of AstraMax Receives Allowance For Patent Updates Status Of FDA's Approval For Treatment Of Astigmatism WINTER PARK, Fla., Feb. 8 /PRNewswire/ -- LaserSight Incorporated (Nasdaq: LASE - news) announced today that it has received notification from the FDA that the Company may begin commercial distribution of its AstraMax(TM) diagnostic workstation. The Company also announced that it has received a Notification of Allowance from the U.S. Patent and Trademark Office for a patent application related to its AstraMax technology. Also, the Company provided an update on the status of the FDA approval for utilizing its LaserScan LSX® precision beam scanning laser system to treat astigmatism. Status of FDA's Approval for Treatment of Astigmatism In December 2000 the Company also filed an additional PMA Supplement requesting that the LSX be approved to treat myopia and myopic astigmatism utilizing the LASIK procedure. The Company subsequently received notification from the FDA that the FDA had completed its initial review and determined that the additional PMA Supplement for LASIK was sufficiently complete to permit review. With the filing of the LASIK supplement in December 2000, we now have two supplements for astigmatism under consideration at the Agency. Approval for the Company's PARK PMA Supplement has taken longer than anticipated. On February 7, 2001 LaserSight received a response to its pending PMA Supplement for the LSX to treat astigmatism utilizing photorefractive keratectomy, and will be preparing its response to the FDA. LaserSight's confidence in receiving approval to treat astigmatism is further strengthened by the fact that the Company now has two PMA Supplements pending with the FDA. Receives Allowance for Patent The AstraMax diagnostic workstation is an integrated refractive workstation designed to provide precise diagnostic measurements of the eye and will be one of the most advanced diagnostic devices offered on the market. The AstraMax will provide topographic information from the anterior and posterior corneal surfaces, provide pachymetry (corneal thickness) and provide photopic pupil size information. In addition, unlike current instruments, the AstraMax will also include anterior corneal measurements from limbus to limbus and provide both photopic and scotopic pupil size measurements. Currently an ophthalmologist or optometrist would need to utilize at least two separate diagnostic instruments to obtain the diagnostic information that the AstraMax can acquire. The diagnostic measurements from the AstraMax can be utilized for a broad spectrum of ophthalmic applications. The AstraMax incorporates virtually instantaneous image acquisition through the use of patented multi-camera technology that provides faster and more accurate measurements than conventional topographers through triangulation and a patented checkered polar grid illumination pattern to uniquely integrate these technologies into a single instrument. An AstraMax integrated workstation can be utilized in both ophthalmic and optometric practices for planning ophthalmic procedures that require precise and accurate measurements of the eye. These procedures include contact lens fitting, cataract extractions, clear lens extractions, and planning for customized laser ablations. In 2000, there were approximately 1450 corneal topographers sold throughout the world. Sales of topographers are expected to grow to 1725 units in 2001 and to 2070 units in 2002. LaserSight believes that an integrated diagnostic workstation like the AstraMax, capable of measuring pachymetry and pupilometry, in addition to anterior and posterior corneal topography, should fill a long expressed need of the market and be able to capture a significant share of the corneal topography market. As part of LaserSight's Astra family of products for the Company's CustomEyes(TM) customized ablation products, the AstraMax workstation will provide refractive surgeons with the precise diagnostic measurements that are required for planning customized ablations with the Company's anticipated AstraPro(TM) software. AstraPro is the proposed surgical planning tool that utilizes the AstraMax's advanced levels of diagnostic measurements for the planning of personalized refractive treatment plans. LaserSight has also received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent related to its AstraMax technology. When issued, this patent will cover a method for simultaneous automatic measurement of the anterior and posterior corneal surfaces, corneal thickness and optical aberrations of the eye. The invention utilizes a wave front measurement technique that incorporates multiple resolution micro-lens arrays and a keratometric target. The Company now holds five issued or allowed patents on the technologies underlying the design and operation of the AstraMax diagnostic workstation, which include use of multiple cameras for accurate corneal surface height measurements, the checkered polar grid and a technology related to wave front measurement that can be incorporated into the instrument. A number of additional patents related to the AstraMax technology are pending. Michael R. Farris, president and chief executive officer of LaserSight commented, ``We are pleased that the patent office continues to recognize the state-of-the-art technology incorporated into the AstraMax and has allowed another one of our patent applications. Our goal is to continue increasing our intellectual property portfolio thereby achieving an even greater differentiation of our refractive and diagnostic technology and products from our competition. The unique capabilities of the AstraMax positions us to offer an integrated diagnostic workstation to ophthalmologists and optometrists not only for use in planning refractive treatments, but also as a diagnostic tool for a broad cross section of other treatments. Being able to offer an ophthalmic instrument with broad application outside of laser refractive surgery presents a unique opportunity for LaserSight to generate AstraMax sales revenues in areas of application that represent markets of greater size than the laser refractive market for this instrument alone.'' The AstraMax diagnostic workstation will be an integral element of LaserSight's planned family of CustomEyes(TM) products for personalized laser refractive treatments. Mr. Farris added, ``CustomEyes represents a new standard of eyecare that goes beyond conventional laser vision correction. By individualizing laser refractive treatments utilizing precision diagnostic measurements in conjunction with a patient-pending algorithm, we will be able to address and control both refractive error and optical aberrations. We believe that our LaserScan LSX state-of-the-art precision beam scanning system combined with the AstraMax diagnostic workstation and AstraPro planning software when available, will offer refractive surgeons the most advanced tools for personalized refractive corrections. We are currently conducting international trials of our ablation planning software, and intend to expand these trials into the U.S. during this year.'' LaserSight introduced the AstraMax diagnostic workstation during the October 2000 meeting of the American Academy of Ophthalmology. The Company plans to commercially launch the product during the meeting of the American Society for Cataract and Refractive Surgery that will be held in San Diego, CA in April of this year. Using the same instrument to simultaneously obtain all measurements necessary to perform custom ablations ensures that all diagnostic data utilized with the AstraPro software during the subsequent phase of personalized treatment planning are aligned to the patient's optical or visual axis. LaserSight plans to incorporate wave front analysis into a later version of the AstraMax. Mr. Farris concluded, ``LaserSight will continue to increase and strengthen its intellectual property portfolio through new patents and licenses. Our overall objective is to leverage our intellectual properties into an on-going stream of revenue related to procedure fees. As our AstraMax diagnostic workstation and later our CustomEyes(TM) family of products for custom ablation is introduced internationally and after approval in the U.S., we anticipate realizing the revenue generating potential of an intellectual property portfolio broad enough to cover aspects of refractive procedures beyond the fundamental corneal ablation for refractive correction.'' LaserSight is a leading supplier of quality technology solutions for laser vision correction. Its products include the LaserScan LSX precision beam scanning spot system, its international research and development activities related to the Astra family of products used to perform custom ablation procedures known as CustomEyes(TM) and its MicroShape family of keratome products. The Astra family of products will include the AstraMax diagnostic work station designed to provide advanced diagnostic measurements of the eye and the AstraPro software, a surgical planning tool that will utilize advanced levels of diagnostic measurements for the planning of custom ablation treatments. In the United States, the Company's LaserScan LSX excimer laser system operating at 200 Hz is approved for the treatment of low to moderate myopia by photorefractive keratectomy. LaserSight has received notification from the FDA that it may begin commercial distribution of its AstraMax(TM) diagnostic workstation and has begun international clinical testing of its CustomEyes(TM) custom ablation program. The MicroShape family of keratome products includes the UltraShaper durable keratome and the UltraEdge keratome blades. This press release contains forward-looking statements regarding future events and future performance of the Company, including statements with respect to anticipated sales revenue, regulatory approvals and commercialization of products, which involve risks and uncertainties that could materially affect actual results. Investors should refer to documents that the Company files from time to time with the Securities and Exchange Commission for a description of certain factors that could cause the actual results to vary from current expectations and the forward looking statements contained in this press release. Such filings include, without limitation, the Company's Form 10-K, Form 10-Q and Form 8-K reports. SOURCE: LaserSight, Inc. |
|
|
|
SOURCE: LaserSight Incorporated LaserSight Completes Clinical Evaluation of LaserScan LSX(R) at 200 Hz LaserSight Will Upgrade U.S. Installed Base WINTER PARK, Fla., Nov. 7 /PRNewswire/ -- LaserSight (Nasdaq: LASE - news), a leader in scanning spot laser technology for refractive surgery, today announced completion of the quality evaluation phase for the 200 Hz repetition rate version of its LaserScan LSX® precision beam scanning spot excimer laser system. The Company also commented on its plan for upgrading the installed base of LaserScan LSX's in the United States to operate at 200 Hz. As previously announced, LaserSight received U.S. Food & Drug Administration approval to advance the laser pulse repetition rate of its LSX system to 200 Hz, which is the fastest pulse rate available in the U.S. market. LaserSight's quality evaluation is not required by any regulatory agency but is LaserSight's self-imposed final phase in the development and commercialization process for a new product or product modification, and is limited to a small number of sites. The internal procedures that the Company has adopted for commercial release of products or product enhancements require this quality evaluation phase, which is above and beyond any other clinical and product testing that was required to ensure conformance with FDA and international standards. The requirement for quality evaluation of the software modifications needed for the upgrade to the 200 Hz further verifies the clinical safety and effectiveness of any product, or modification, prior to commercial release. Michael R. Farris, president and chief executive officer of LaserSight, commented, ``LaserSight holds itself to this additional self-imposed standard of quality evaluation testing to ensure delivery of the highest level of system performance and clinical benefits. We are committed to bringing new products to the market as quickly as possible, however, we will go beyond the minimum standards required by the regulatory agencies to ensure physician and patient satisfaction.'' The 200 Hz laser pulse repetition rate, which is significantly higher than that available in other refractive laser systems, combined with the spatial resolution and precision achievable only with a small beam scanning spot system, are two significant technical advantages of the LaserScan LSX. The combination of its smaller spot size, highest pulse repetition rate and lowest laser fluence makes the LSX unique when compared to all other refractive laser systems currently approved in the U.S. market. Smoothness of the corneal surface after laser treatment is a very important clinical consideration. With its gentle low energy fluence and <1mm laser spot the LaserScan LSX produces a very smooth ablation profile. The combination of low energy and small spot size results in removal of the smallest amount of corneal tissue per laser pulse of any approved laser. As previously announced, the quality evaluation phase was started shortly after the Company received FDA approval of LaserSight's PMA supplement for 200 Hz, and was conducted at four clinical sites. Gail Martin, M.D., of Carolina Eye Associates, a LaserSight reference center located in Southern Pines, NC, was one of the physicians participating in the quality evaluation phase. Dr. Martin commented, ``Increasing the laser to 200 Hz really makes a flying spot scanning system extremely efficient. I am seeing better quality and smoother interfaces, with 80 percent of the patients treated at 200 Hz achieving one day post-operative best uncorrected visual acuity (BUCVA) of 20/25 or better. The centration of ablations has been excellent based on visual results and topographical analysis.'' A second physician in the evaluation, Allan Robbins, M.D., of Robbins Eye Associates, Rochester, NY, commented, ``What I have found is that operating the LSX at 200 Hz makes the entire procedure much more user friendly for both the patient and physician. By dramatically shortening the treatment times, patient fixation is facilitated and the risk of decentrations diminished. Combining the new speed with the low energy levels of the LSX results in a much more pleasant experience for both the patient and the surgeon.'' The Company expects that by the end of the month it will provide the 200 Hz upgrade to all LSX systems installed in the U.S. All future LSX shipments will be made with the laser operating at the 200 Hz pulse repetition rate. In the international market the Company has been delivering new laser systems operating at the 200 Hz repetition rate for the past year, and has upgraded its installed base of LSX systems to operate at 200 Hz. Currently the Company has over 130 laser systems that operate at this higher pulse frequency. Mr. Farris continued, ``We are committed to offering users of our LSX laser system the latest state-of-the-art developments in excimer laser technology. As surgeons migrate from first-generation broad beam lasers to advanced technology precision scanning spot systems, LaserSight continues to maintain its competitive position by offering the smallest scanning laser beam, with the lowest fluence, or energy delivery, at the fastest repetition rate available today.'' Mr. Farris continued, ``We believe it is the patient who ultimately benefits from the 200 Hz upgrade.'' ``Our ability to upgrade the LaserScan LSX laser platform to 200 Hz operation by only changing software demonstrates how the system was designed to facilitate future significant advances in system operation. After FDA approval, we will be able to install the AccuTrack® eye tracking system and expand the range of clinical treatments, once again, through software changes only,'' commented Rick Davis, LaserSight's vice president of engineering. ``We intend to continue our tradition of leadership in technological advancements through the introduction of a series of new innovative products for refractive correction.'' LaserSight is a leading supplier of quality technology solutions for laser vision correction. The Company markets its LaserScan LSX® excimer laser systems and MicroShape(TM) family of keratome products in more than 30 countries through a network of distribution partners and a direct sales force. In the United States, the Company's LaserScan LSX excimer laser system is approved for the treatment of low to moderate myopia by photorefractive keratectomy. This press release contains forward-looking statements regarding future events and future performance of the Company, including statements with respect to clinical outcomes, anticipated regulatory approvals and commercialization of products, which involve risks and uncertainties that could materially affect actual results. Investors should refer to documents that the Company files from time-to-time with the Securities and Exchange Commission for a description of certain factors that could cause the actual results to vary from current expectations and the forward-looking statements contained in this press release. Such filings include, without limitation, the Company's Form 10-K, Form 10-Q and Form 8-K reports. SOURCE: LaserSight Incorporated Return to the News Page |
|
|
|
Robbins Laser Site Now Offering the LaserScan LSXT Excimer Laser August 24, 2000 Rochester New York - The Robbins Laser Site is proud to announce the purchase of the LaserScan LSXT, the latest generation in Gentle Touch, Flying Spot excimer laser technology to reduce or eliminate nearsightedness (myopia). The Robbins Laser Site is the first eye center in the Rochester area to offer this revolutionary scanning excimer Laser. The LaserScan LSXT is a product of LaserSight Technologies, Inc. and offers one of the largest specified optical zones of any approved laser. A true scanning spot laser, this laser offers large round optical zones, a 0.8 mm spot beam and the least energy per pulse, providing very smooth ablations for excellent quality of vision. These features of the laser may also reduce the effects of nighttime glare, haze, and halos, which are seen with older laser technology. "LaserSight is pleased to have the Robbins Laser Site as a U.S. Reference Center based on the excellence of their clinical experience and outcomes, their reputation and outstanding staff", commented Michael R. Farris, President and CEO of LaserSight Incorporated. Mr. Farris continued, "Patients in the Rochester area are very fortunate to access to this center of excellence for refractive surgery, and with the recent purchase of the LaserScan LSXT, Robbins Laser Site now has the latest in precision beam scanning excimer laser technology." Since the facility has been designated as an U.S. Reference Center, Dr. Robbins will have the responsibility for training U.S. surgeons, conducting clinical trials, and the eye center will have the latest upgrades to the laser as they are available. One example of this is the upgrade to 200 Hz. Currently the LSXT is approved to operate at a 100 Hz repetition rate, which is faster than any excimer laser approved in the U.S. LaserSight expects their 200 Hz system to be approved by the end of the month, and the Robbins Laser Site is slated to be one of the first U.S. facility to receive this upgrade. Dr. Allan Robbins is Board Certified LASIK surgeon and former clinical investigator for VISX. "My decision to purchase the LaserScan LSXT was based on over 7 years of excimer experience combined with hundreds of hours of research and study", stated Dr. Allan Robbins. He continued "After discussing the choices with other innovators and leaders around the world, it was apparent that LaserSight offered the most technologically advanced solutions for my patients." LaserSight excimer lasers have been used outside the United States since 1993. Over 300 lasers exist outside the United States. Please contact Wendy Corcoran at 716-787-2020 for additional information or log onto www.robbinslasersite.com. **Please see the attached for an abbreviated U. S. Conditions of Approval The LaserScan LSX Eximer Laser is intended for myopia PRK for the reduction or elimination of myopia ranging from -1.0 diopters (D) to < -6.0 D with = 1.0 D of astigmatism. PRK is contraindicated in patients with the following conditions: Pregnant or nursing, central corneal scars, Keratoconous, and others. PRK is not recommended for patients with a history of ophthalmic Herpes Simplex or Herpes Zoster. Detailed information on the indications, contraindications, warnings, and conditions of approval are available upon request from your physician. |
|
|